Avenzo Therapeutics Raises $150 Million for Oncology Platform

Located in the United States, Avenzo Therapeutics has raised $150 million in an early-stage funding round to develop their oncology portfolio.  

The initial financing round saw input from Deep Track Capital, Sands Capital, and Sofinnova Investments. This brings the funds to a total of just under $350 million.  

The financing round will aid Avenzo with the development of their oncology platform and top candidate, AVZO-021, a treatment for solid tumours.  

Athena Countouriotis, the head executive at Avenzo, stated, “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients.”  

Countouriotis went on to add, “With the support of our new and existing investors, including OrbiMed, Foresite Capital, SR One, Lilly Asia Ventures, and Surveyor Capital (a Citadel company), we are in a strong position to advance our potentially best-in-class CDK2 inhibitor, AVZO-021, expand our pipeline with additional assets, and continue to grow our team.”  

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.